Unlike the responses in breast cancer cell lines with high MMP-11 expression, the therapeutic responses in patients with breast cancer may be highly heterogeneous and affected by various microenvironments and immune components, which could have effects on clinical applications. This evidence concerns the gene MMP11 and breast carcinoma.